Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics is a biotech firm working on gene-editing technology to potentially cure serious diseases by fixing DNA directly inside the body.
Is Intellia Therapeutics, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Pioneering technology with the potential to treat previously incurable diseases. Worth weighing: No current revenue or profit from product sales. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Intellia Therapeutics, Inc. actually fallen?
Over the last 2 years of daily prices, Intellia Therapeutics, Inc. fell as much as −75% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Commercialisation of a successful gene therapy
Inability to bring a product to market
What does Intellia Therapeutics, Inc. do?
Intellia is essentially a scientific research powerhouse focused on CRISPR technology, which acts like a pair of molecular scissors to edit faulty genes. Because they are still in the testing phase for their treatments, they aren't yet making a profit from sales, meaning they rely on cash reserves to fund their expensive lab work. Everything hinges on their progress in clinical trials, since future success depends entirely on proving these complex treatments are safe and effective for patients.
On our factor screen it looks strongest on value and quality, and weakest on growth.
- !Pays no dividend - the whole return rides on the share price
- !Revenue slipped about 10% over the year
- !Thin profits - turns only about 0% of sales into profit
- ✓Low debt - a sturdier balance sheet
- Pioneering technology with the potential to treat previously incurable diseases
- Strong intellectual property portfolio in the CRISPR field
- High interest from the scientific and medical community
- Quality screens low (27/100)
- Growth screens low (4/100)
- Momentum screens low (13/100)
- Income screens low (16/100)
- Clinical trial failures could halt development entirely
What do Intellia Therapeutics, Inc.'s numbers mean?
How much money does Intellia Therapeutics, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Intellia Therapeutics, Inc. pay a dividend?
No - Intellia Therapeutics, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Intellia Therapeutics, Inc. report earnings, and how did recent quarters go?
Intellia Therapeutics, Inc. is next scheduled to report on about 2026-08-06 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-11 | $-0.90 | $-0.81 | Beat +10% |
| 2026-02-26 | $-0.96 | $-0.83 | Beat +14% |
| 2025-11-06 | $-0.98 | $-0.92 | Beat +7% |
| 2025-08-07 | $-1.01 | $-0.98 | Beat +3% |
| 2025-05-08 | $-1.27 | $-1.10 | Beat +13% |
| 2025-02-27 | $-1.32 | $-1.27 | Beat +4% |
Across the last 6 quarters here, Intellia Therapeutics, Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Intellia Therapeutics, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Intellia Therapeutics, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Pioneering technology with the potential to treat previously incurable diseases
- Strong intellectual property portfolio in the CRISPR field
- High interest from the scientific and medical community
- No current revenue or profit from product sales
- High cash burn rate to support research
- Highly volatile share price compared to the broader market
- Clinical trial failures could halt development entirely
- Regulatory hurdles could delay or block product launches
- Need for future funding could lead to diluting existing shareholders
The write-up's own warning lights — if these start happening, the case above changes.
- A permanent halt to all clinical trial activity
- A major breakthrough by a competitor that renders their technology obsolete
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.